Thiopurines Used to Treat IBD May Increase Risk of Leukemia

Share this content:

the Cancer Therapy Advisor take:

Thiopurines, a class of immunosuppressive agents widely used to treat irritable bowel disease (IBD) and rheumatoid arthritis, were found to increase the risk of myeloid disorders seven times.

 

In a prospective observational study conducted in France and published in the journal Clinical Gastroenterology and Hepatology, researchers found that past use of thiopurines such as azathioprine and 6-mercaptopurine were associated with a significantly increased risk of developing acute myeloid leukemia (AML) or myelodisplastic syndrome, but only in the IBD patient population.

 

Neither the risk of myeloid disorders among the overall IBD population compared with the general population or the risk of myeliod disorders among patients with IBD and ongoing thiopurine therapy were increased. Despite the seven-fold increase in risk for patients with past thiopurine treatment, the absolute risk is about 1 in 10,000 patients developing a myeloid disorder.

 

Azathioprine and 6-mercaptopurine may also be associated with a increased risk of a rare type of lymphoma, hepatosplenic T-cell lymphoma, in those with irritable bowel disease, but whether the thiopurines or the disease are the cause of the cancer has not yet been established.

Alvocidib Receives Orphan Drug Designation for AML
Thiopurines were found to increase the risk of myeloid disorders seven times.
Immunosuppressive drugs called thiopurines have been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among inflammatory bowel disease patients. IBD can negatively impact an individual's life and result in a significant amount of medical bills.
READ FULL ARTICLE From Science Daily

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs